Stockholm Ischemic Heart Disease Study
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
Stockholm Ischemic Heart Disease Study On the Web |
|
American Roentgen Ray Society Images of Stockholm Ischemic Heart Disease Study |
|
Risk calculators and risk factors for Stockholm Ischemic Heart Disease Study |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
The Stockholm Ischemic Heart Disease study is a randomized open label trial that assessed the effect of clofibrate and nicotinic acid vs placebo on ischemic heart disease mortality.
Study Description
| Study Description | |
| Study Design | |
| Allocation | Randomized |
| Endpoint | Ischemic heart disease mortality |
| Masking | Open label |
| Study Details | |
| Primary Purpose | |
| Condition | Survivors of a myocardial infarction |
| Study Arms | Clofibrate and nicotinic acid Control |
| Population Size | 555 subjects |
Publications
The Stockholm Ischemic Heart Disease study revealed a 36% decrease in ischemic heart disease mortality among patients ho recieved the treatment vs control, an effect most likely related to the triglycerides plasma concentration particularly among patients with a triglyceride level higher than 1.5 mmol/l and those who had a decrease in the serum triglyceride by at least 30%.